So let me see if this poor marsupial brain has got this right.
We've had two significant trial readouts this week and both missed their primary end points.
So either the products aren't up to scratch or the end points weren't appropriate.
As there is significant evidence that the products are good
Then we can conclude that the primary end points were inappropriate.
If so, what is the cause of this massive design failure?
Ann: Mesoblast Update on COVID-19 ARDS Trial, page-535
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.57 |
Change
-0.210(11.8%) |
Mkt cap ! $1.792B | |||
| Open | High | Low | Value | Volume |
| $1.72 | $1.74 | $1.52 | $15.63M | 9.716M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 5127 | $1.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 39613 | 3 |
View Market Depth
| Last trade - 16.10pm 15/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |